Analgecine (AGC), an analgesic for lumbar pain in patients with spinal degenerative diseases, has been shown to inhibit M1-type polarization and promote M2-type polarization by inhibiting TLR4/MyD88/NF-κB signaling pathway, which reduced neuroinflammation during cerebral ischemia (Yang et al., 2021). This evidence concerns the gene TLR4 and brain ischemia.